Table S1: Relevant outcomes in trials of oral antihypertensive therapy for severe hypertension

Mortality	
BP control	'Successful' treatment of BP (as defined)
	% women requiring more than one dose of antihypertensive agent
	New 'hypertensive crisis' following initial control of BP
	% of patients with BP decrease at 4 hr
	% of patients with BP decrease at 24 hr
	% of patients with target BP of 140/90mmHg
	Decrease in sBP in mmHg
	Decrease in dBP in mmHg
	% patients requiring additional antihypertensive therapy
	% patients with hypotension (as defined)
	% patients who were hospitalised due to any cause*
	Time taken to achieve target BP
Adverse effects reported	Non-fatal cerebrovascular, cardiovascular and cardiopulmonary events (such as stroke, myocardial infarction, angina, silent ischemia, arrhythmias, congestive heart failure, kidney failure, and acute pulmonary edema)

BP (blood pressure), dBP (diastolic blood pressure), sBP (systolic blood pressure)

Table S2: Nifedipine po/sl vs. Hydralazine IV: Perinatal Outcomes

Perinatal Outcome	Summary Statistic
Caesarean section	RR 0.85 [0.56, 1.29] I^2 = NA 1 trial, N=26
Adverse fetal heart rate effects	RD 0.00 [-0.03, 0.03] I^2 = NA 1 trial, N=255
Perinatal death	RD 0.01 [-0.03, 0.06] I^2 = 11% 4 trials, N=246
Stillbirth	RD 0.00 [-0.03, .03] I^2 = NA 3 trials, N=196
Neonatal death	RD 0.04 [-0.06, 0.13] I^2 = 54% 3 trials, N=196
Apgar score <7 at 5 min	RR1.02 [0.50, 2.05] I^2 = NA 1 trial, N=126

Table S3: Nifedipine po/sl vs. Labetalol IV: Maternal and Perinatal Outcomes

Maternal Outcome	Summary Statistic
Successful treatment	RR 1.02 [0.95, 1.09] I^2 = 0 2 trials, N=100
Required > one dose of antihypertensive	RR 0.94 [0.70, 1.25] I^2 = 0% 2 trials, N=62
Required additional antihypertensive therapy	RR 1.00 [0.33, 3.03] I^2 = NA 2 trials, N=100
New hypertensive crisis following initial BP control	RR 0.55 [0.12, 2.58] I^2 = NA 1 trial, N=50
Time taken to achieve target BP	WMD -18.60 [-46.20, 9.00] I^2 = NA 1 trial, N=9
Maternal mortality	RD -0.00 [-0.07, 0.07] I^2 = NA 1 trial, N=50
Maternal hypotension	RD 0.03 [-0.06, 0.13] I^2 = 0% 2 trials, N=62
Perinatal Outcome	**Summary Statistic**
Caesarean section	RR 0.1.23 [0.76, 1. 98] I^2 = NA 1 trial, N=50
Adverse fetal heart rate effects	RD 0.06 [-0.16, 0.28] I^2 = NA 1 trial, N=29
Perinatal death	RD 0.00 [-0.07, 0.07] I^2 = NA 1 trial, N=50
Stillbirth	RD 0.00 [-0.07, .07] I^2 = NA 1 trial, N=50
Neonatal death	RD 0.00 [-0.07, 0.07] I^2 = 54% 1 trials, N=50
Apgar score <4 at 1 min	RR0.47 [0.05, 4.60] I^2 = NA 1 trial, N=29
Admission to NICU	RR 1.00 [0.18, 5.51] I^2 = NA 1 trial, N=50

Table S4: Methyldopa vs. other agents: Maternal and Perinatal Outcomes

	MTD vs. Labetalol	MTD vs. Atenolol	MTD vs. Ketanserin
Maternal Outcome			
Successful treatment	RR 1.18 [0.75, 1.85] I^2 = NA 1 trial, N=72	–	–
Adverse effects reported			
Changed drugs due to side effects	RD 0.00 [-0.05, 0.05] I^2 = NA 1 trial, N=72	RD 0.00 [-0.06, 0.06] I^2 = NA 1 trial, N=60	–
Relief of signs or symptoms of pre-eclampsia	–	RR 1.18 [0.63, 2.20] I^2 = NA trial, N=60	RR 0.52 [0.34, 0.81] I^2 = NA trial, N=60
Headache	RR 0.37 [0.02, 8.82] I^2 = NA 1 trial, N=72	–	–
Perinatal Outcome			
Caesarean section	RR 1.18 [0.77, 1.80] I^2 = NA 1 trial, N=72	–	–
Perinatal death	RD 0.05 [-0.03, 0.14] I^2 = NA 1 trial, N=72	RD 0.00 [-0.13, 0.13] I^2 = NA 1 trial, N=60	RD -0.03 [-0.17, 0.11] I^2 = NA 1 trial, N=60
Stillbirth	RD 0.00 [-0.05, 0.05] I^2 = NA 1 trial, N=72	RD 0.00 [-0.09, 0.09] I^2 = NA 1 trial, N=60	RD 0.03 [-0.05, 0.12] I^2 = NA 1 trial, N=60
Neonatal death	RD -0.05 [-0.14, 0.03] I^2 = NA 1 trial, N=72	RD 0.00 [-0.09, 0.09] I^2 = NA 1 trial, N=60	RD -0.07 [-0.19,0.06] I^2 = NA 1 trial, N=60
Apgar score <4 at 1 min	–	RR1.18 [0.93, 1.50] I^2 = NA 1 trial, N=60	RR0.96 [0.82, 1.12] I^2 = NA 1 trial, N=60
Admission to NICU	RR 0.94 [0.58, 1.52] I^2 = NA 1 trial, N=72	–	–